中等症から重症喘息の成人患者を対象としたアムリテリマブの用量範囲試験

基本情報

NCT ID

NCT05421598

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

446

治験依頼者名

Sanofi

概要

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: * The study duration (per participant) will be up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study. * The randomized treatment duration will be up to approximately 60 weeks. * The scheduled number of visits will be 13.

対象疾患

介入

依頼者（Sponsor）